Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
NAGE 
Niagen Bioscience, Inc. (NAGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: NAGE (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.4
1 Year Target Price $11.4
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 102.65% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 836.53M USD | Price to earnings Ratio 59 | 1Y Target Price 11.4 |
Price to earnings Ratio 59 | 1Y Target Price 11.4 | ||
Volume (30-day avg) 4 | Beta 1.95 | 52 Weeks Range 3.28 - 14.69 | Updated Date 08/18/2025 |
52 Weeks Range 3.28 - 14.69 | Updated Date 08/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.07% | Operating Margin (TTM) 15.66% |
Management Effectiveness
Return on Assets (TTM) 12.21% | Return on Equity (TTM) 33.47% |
Valuation
Trailing PE 59 | Forward PE 65.36 | Enterprise Value 743633586 | Price to Sales(TTM) 7.75 |
Enterprise Value 743633586 | Price to Sales(TTM) 7.75 | ||
Enterprise Value to Revenue 6.89 | Enterprise Value to EBITDA 50.62 | Shares Outstanding 78769696 | Shares Floating 51792712 |
Shares Outstanding 78769696 | Shares Floating 51792712 | ||
Percent Insiders 34.44 | Percent Institutions 30.6 |
Upturn AI SWOT
Niagen Bioscience, Inc.
Company Overview
History and Background
Niagen Bioscience, Inc. does not exist as a publicly traded US stock. The term 'Niagen' is associated with nicotinamide riboside (NR), a form of vitamin B3 marketed by ChromaDex Corp (CDXC). Assuming the query intended to focus on ChromaDex, the following information is provided based on CDXC.
Core Business Areas
- Ingredients: Research, development, and commercialization of novel, science-backed ingredients, primarily nicotinamide riboside (NR), marketed under the brand name Niagen.
- Finished Products: Development and sale of dietary supplements and skincare products containing Niagen and other proprietary ingredients.
- Licensing: Licensing its Niagen technology to other companies for use in their products.
Leadership and Structure
ChromaDex's leadership team consists of a CEO, CFO, and other key executives. The company has a Board of Directors overseeing its operations.
Top Products and Market Share
Key Offerings
- Tru Niagen: ChromaDex's flagship product, a dietary supplement containing nicotinamide riboside (NR). Market share data is not readily available, but Tru Niagen is a leading NR supplement. Competitors include Elysium Health (Basis), Life Extension (NAD+ Cell Regenerator), and various other supplement brands offering NR or NAD+ precursors.
- marketShare:
- numberOfUsers:
- revenue:
- Niagen Ingredients: ChromaDex sells Niagen as an ingredient to other companies for use in their products. The revenue from this segment is significant, but precise figures aren't publicly disclosed. Market share is difficult to ascertain due to the variety of applications. Competitors are other suppliers of NAD+ precursors or related ingredients.
- marketShare:
- numberOfUsers:
- revenue:
Market Dynamics
Industry Overview
The market for dietary supplements and anti-aging products is large and growing, driven by increasing consumer interest in health and wellness. The market for NAD+ precursors, in particular, is expanding.
Positioning
ChromaDex is positioned as a science-backed leader in the NAD+ precursor market, with strong intellectual property protection and clinical research supporting its products. Its competitive advantage lies in its patented Niagen ingredient and its commitment to scientific validation.
Total Addressable Market (TAM)
The global dietary supplements market is estimated to be worth hundreds of billions of dollars. ChromaDex's TAM specifically relates to the NAD+ boosting sector and healthy aging supplements. It is positioned to capture a significant, yet still relatively small, portion of this large market.
Upturn SWOT Analysis
Strengths
- Patented Niagen ingredient
- Strong scientific backing
- Established brand recognition
- Growing revenue stream
Weaknesses
- Reliance on a single key ingredient (Niagen)
- High marketing expenses
- Profitability concerns
- Litigation costs
Opportunities
- Expanding into new markets and product categories
- Increasing awareness of NAD+ benefits
- Partnerships with major consumer brands
- Further research demonstrating the benefits of Niagen
Threats
- Competition from other NAD+ precursors
- Regulatory scrutiny of dietary supplements
- Potential patent challenges
- Changes in consumer preferences
Competitors and Market Share
Key Competitors
- ELYS
- MNMD
Competitive Landscape
ChromaDex faces competition from other companies marketing NAD+ precursors and anti-aging products. Its advantage lies in its patented Niagen ingredient and its scientific validation, but it must continue to innovate and maintain its brand reputation.
Growth Trajectory and Initiatives
Historical Growth: Assess CDXC's revenue growth rate over the past few years.
Future Projections: Consult analyst estimates for CDXC's future revenue and earnings growth. Take into account the potential market size for Niagen and other NAD+ precursors.
Recent Initiatives: Highlight CDXC's recent product launches, partnerships, and research initiatives.
Summary
ChromaDex, the company behind Niagen, holds a strong position in the NAD+ precursor market due to its patented ingredient and scientific validation. While facing competition and profitability challenges, it benefits from the growing interest in healthy aging. Future success depends on continued innovation, market expansion, and effective management of expenses and potential patent challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ChromaDex Corp. Investor Relations
- Market Research Reports
- Company Filings (SEC)
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated. Financial performance is based on historical data and projections. The AI-based rating is subjective and should not be the sole basis for investment decisions. Invest with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Niagen Bioscience, Inc.
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2008-07-15 | CEO & Director Mr. Robert N. Fried | ||
Sector Healthcare | Industry Biotechnology | Full time employees 104 | Website https://www.niagenbioscience.com |
Full time employees 104 | Website https://www.niagenbioscience.com | ||
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.